These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38561048)

  • 1. Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019.
    Clopper BR; Zhou Y; Tannis A; Staat MA; Rice M; Boom JA; Sahni LC; Selvarangan R; Harrison CJ; Halasa NB; Stewart LS; Weinberg GA; Szilagyi PG; Klein EJ; Englund JA; Rha B; Lively JY; Ortega-Sanchez IR; McMorrow ML; Moline HL
    J Pediatr; 2024 Aug; 271():114045. PubMed ID: 38561048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study.
    Thampi N; Knight BD; Thavorn K; Webster RJ; Lanctot K; Hawken S; McNally JD
    CMAJ Open; 2021; 9(4):E948-E956. PubMed ID: 34667075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
    McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
    J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
    Diehl JL; Daw JR; Coley KC; Rayburg R
    J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; Krilov LR; DeVincenzo JP; Checchia PA; Halasa N; Simões EA; Domachowske JB; Forbes ML; Pannaraj PS; McBride SJ; McLaurin KK; Kumar VR; Ambrose CS
    Am J Perinatol; 2017 Jan; 34(1):51-61. PubMed ID: 27233106
    [No Abstract]   [Full Text] [Related]  

  • 7. The burden of respiratory syncytial virus infection in young children.
    Hall CB; Weinberg GA; Iwane MK; Blumkin AK; Edwards KM; Staat MA; Auinger P; Griffin MR; Poehling KA; Erdman D; Grijalva CG; Zhu Y; Szilagyi P
    N Engl J Med; 2009 Feb; 360(6):588-98. PubMed ID: 19196675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of care for children hospitalized with respiratory syncytial virus (RSV) associated lower respiratory infection in Kenya.
    Nyiro JU; Nyawanda BO; Mutunga M; Murunga N; Nokes DJ; Bigogo G; Otieno NA; Lidechi S; Mazoya B; Jit M; Cohen C; Moyes J; Pecenka C; Baral R; Onyango C; Munywoki PK; Vodicka E
    BMC Public Health; 2024 Sep; 24(1):2410. PubMed ID: 39232690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
    Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
    Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inpatient burden of respiratory syncytial virus (RSV) in Switzerland, 2003 to 2021: an analysis of administrative data.
    Stucki M; Lenzin G; Agyeman PK; Posfay-Barbe KM; Ritz N; Trück J; Fallegger A; Oberle SG; Martyn O; Wieser S
    Euro Surveill; 2024 Sep; 29(39):. PubMed ID: 39328156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study.
    Do LAH; Vodicka E; Nguyen A; Le TNK; Nguyen TTH; Thai QT; Pham VQ; Pham TU; Nguyen TN; Mulholland K; Cao MT; Le NTN; Tran AT; Pecenka C
    BMC Infect Dis; 2023 Feb; 23(1):73. PubMed ID: 36747128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.
    Bhuiyan MU; Luby SP; Alamgir NI; Homaira N; Sturm-Ramirez K; Gurley ES; Abedin J; Zaman RU; Alamgir A; Rahman M; Ortega-Sanchez IR; Azziz-Baumgartner E
    J Glob Health; 2017 Jun; 7(1):010412. PubMed ID: 28702175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR; Fergie J; Goldstein M; Brannman L
    Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.
    Hall CB; Weinberg GA; Blumkin AK; Edwards KM; Staat MA; Schultz AF; Poehling KA; Szilagyi PG; Griffin MR; Williams JV; Zhu Y; Grijalva CG; Prill MM; Iwane MK
    Pediatrics; 2013 Aug; 132(2):e341-8. PubMed ID: 23878043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
    Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
    Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.